美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

AgomAb Therapeutics

11.25

-0.2900-2.51%

盘后：11.250.00000.00%16:10 EDT

成交量：1.74万

成交额：19.68万

市值：5.54亿

市盈率：-7.56

高：11.55

开：11.38

低：11.05

收：11.54

52周最高：17.45

52周最低：9.00

股本：4,924.80万

流通股本：1,250.00万

量比：0.36

换手率：0.14%

股息：- -

股息率：- -

每股收益(TTM):-1.4881

每股收益(LYR):-168.1598

净资产收益率：-39.22%

总资产收益率：-20.58%

市净率：-2.81

市盈率(LYR):-0.07

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

Agomab获美国专利授权肺靶向吸入式ALK5小分子抑制剂AGMB-447进入特发性肺纤维化治疗研发阶段

Leerink Partners首次覆盖AgomAb Therapeutics，给予“跑赢大盘”评级，目标价36美元

旗舰企业 Generate Biomedicines 希望在美国 IPO 中获得 22 亿美元估值

异动解读 | 新股上市遇冷，AgomAb Therapeutics盘中大跌18.72%

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/AGMB"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AGMB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","market":"US","secType":"STK","nameCN":"AgomAb Therapeutics","latestPrice":11.25,"timestamp":1780084800000,"preClose":11.54,"halted":0,"volume":17438,"hourTrading":{"tag":"盘后","latestPrice":11.25,"preClose":11.25,"latestTime":"16:10 EDT","volume":2,"amount":22.5,"timestamp":1780085405017,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.025129982668977396,"floatShares":12500000,"shares":49248000,"eps":-1.488082,"marketStatus":"休市中","change":-0.29,"latestTime":"05-29 16:00:00 EDT","open":11.38,"high":11.55,"low":11.05,"amount":196799,"amplitude":0.043328,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.488082,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1780300800000},"marketStatusCode":7,"adr":0,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":11.54,"postHourTrading":{"tag":"盘后","latestPrice":11.25,"preClose":11.25,"latestTime":"16:10 EDT","volume":2,"amount":22.5,"timestamp":1780085405017,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.3603532853931746},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","floatShares":12500000,"roa":"-20.58%","roe":"-39.22%","lyrEps":-168.159829,"volumeRatio":0.3603532853931746,"shares":49248000,"dividePrice":0,"high":11.55,"amplitude":0.043328,"preClose":11.54,"low":11.05,"week52Low":9,"pbRate":"-2.81","week52High":17.4528,"institutionHeld":0,"latestPrice":11.25,"eps":-1.488082,"divideRate":0,"volume":17438,"delay":0,"ttmEps":-1.488082,"open":11.38,"prevYearClose":16,"prevWeekClose":11.5,"prevMonthClose":10.85,"prevQuarterClose":10.49,"fiveDayClose":10.94,"twentyDayClose":10.85,"sixtyDayClose":14.68},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AGMB\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AGMB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AGMB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1773892800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AGMB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AGMB","date":"2026-05-29","current":-7.560067,"percent":0.792208,"low":-14.725744,"twenty":-13.4527,"median":-9.998785,"eighty":-7.794875,"high":-7.088561,"avg":-10.577011,"sd":2.538082,"marketCap":568321631},"quantilePoints":[{"date":"2026-02-06","current":-14.293959,"twenty":-14.293959,"median":-14.293959,"eighty":-14.293959,"marketCap":779788464},{"date":"2026-02-13","current":-13.901135,"twenty":-14.202947,"median":-13.85921,"eighty":-13.805127,"marketCap":763217959},{"date":"2026-02-20","current":-13.975141,"twenty":-14.020702,"median":-13.811207,"eighty":-13.436782,"marketCap":760781120},{"date":"2026-02-27","current":-14.297833,"twenty":-14.274685,"median":-13.837477,"eighty":-13.631029,"marketCap":780275831},{"date":"2026-03-06","current":-12.944797,"twenty":-14.315694,"median":-13.869306,"eighty":-13.479283,"marketCap":692549629},{"date":"2026-03-13","current":-12.71107,"twenty":-14.294734,"median":-13.805127,"eighty":-12.961754,"marketCap":677928595},{"date":"2026-03-20","current":-11.600011,"twenty":-14.274685,"median":-13.584093,"eighty":-12.695924,"marketCap":618957093},{"date":"2026-03-27","current":-10.84065,"twenty":-14.216331,"median":-13.160447,"eighty":-12.395453,"marketCap":578505566},{"date":"2026-04-02","current":-10.748527,"twenty":-14.066263,"median":-13.052487,"eighty":-11.414439,"marketCap":574119256},{"date":"2026-04-10","current":-9.193391,"twenty":-13.930737,"median":-12.827934,"eighty":-10.709469,"marketCap":497602513},{"date":"2026-04-17","current":-10.018749,"twenty":-13.86294,"median":-12.650405,"eighty":-9.901184,"marketCap":545851924},{"date":"2026-04-24","current":-9.622204,"twenty":-13.825362,"median":-12.457995,"eighty":-9.650988,"marketCap":521483535},{"date":"2026-05-01","current":-7.206485,"twenty":-13.809991,"median":-11.744798,"eighty":-9.486381,"marketCap":528794052},{"date":"2026-05-08","current":-7.639457,"twenty":-13.779732,"median":-11.111376,"eighty":-9.258769,"marketCap":562411874},{"date":"2026-05-15","current":-7.446972,"twenty":-13.702513,"median":-10.748527,"eighty":-8.300034,"marketCap":543697644},{"date":"2026-05-22","current":-7.434647,"twenty":-13.568448,"median":-10.364346,"eighty":-8.115636,"marketCap":538772846},{"date":"2026-05-29","current":-7.796965,"twenty":-13.4527,"median":-9.998785,"eighty":-7.794875,"marketCap":568321631}],"updateTime":1780159835423},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AGMB\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1184179798","title":"Agomab获美国专利授权 肺靶向吸入式ALK5小分子抑制剂AGMB-447进入特发性肺纤维化治疗研发阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1184179798","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184179798?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522815,"startTime":"0","endTime":"0","summary":"生物制药企业AgomAb Therapeutics宣布，其研发的肺靶向吸入式ALK5小分子抑制剂AGMB-447已获得美国专利授权。该药物目前正针对特发性肺纤维化适应症开展临床前研究，通过精准抑制肺泡区域的TGF-β信号通路，有望为患者提供创新治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119430627","title":"Leerink Partners首次覆盖AgomAb Therapeutics，给予“跑赢大盘”评级，目标价36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119430627","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119430627?lang=zh_cn&edition=fundamental","pubTime":"2026-03-03 19:56","pubTimestamp":1772538974,"startTime":"0","endTime":"0","summary":"投资银行Leerink Partners宣布启动对生物技术公司AgomAb Therapeutics（AGMB）的研究覆盖，并给予“跑赢大盘”评级。该机构为该公司设定了36美元的目标股价，显示出对其未来增长潜力的积极预期。\n此次覆盖标志着市场对AgomAb Therapeutics研发管线的关注升温。Leerink Partners的看好评级基于对公司核心技术与业务前景的深入评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613789435","title":"旗舰企业 Generate Biomedicines 希望在美国 IPO 中获得 22 亿美元估值","url":"https://stock-news.laohu8.com/highlight/detail?id=2613789435","media":"路透中文","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613789435?lang=zh_cn&edition=fundamental","pubTime":"2026-02-23 19:54","pubTimestamp":1771847674,"startTime":"0","endTime":"0","summary":"更新版 3-旗舰企业 Generate Biomedicines 希望在美国 IPO 中获得 22 亿美元估值在第 3、6、7 段添加分析师评论Arasu Kannagi Basil路透2月23日 - 药物开发商Generate Biomedicines周一表示，该公司在美国首次公开募股的目标估值将高达21.7亿美元，从而进入上市步伐加快的生物技术市场。Aktis Oncology AKTS.O、Agomab Therapeutics AGMB.O、Veradermics MANE.N、Eikon Therapeutics EIKN.O和SpyGlass Pharma SGP.O今年已经登陆美国资本市场。\"Generate公司用于治疗严重哮喘的主要候选产品GB-0895正在进行后期试验。预计这项研究将于 2028 年上半年全部完成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL4S3ZJ0Q2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","IE0009355771.USD","LU1244550494.USD","MANE","EIKN","IE00BKVL7J92.USD","IE0004091025.USD","AMGN","LU2750360997.AUD","LU0234570918.USD","LU1162221912.USD","BK4139","BK4516","LU2237443622.USD","LU1868836757.USD","LU0795875169.SGD","LU2265009873.SGD","IE00B2B36J28.USD","BK4127","BK4566","BK4534","LU1868836914.USD","GSX","IE00BJJMRZ35.SGD","LU1804176565.USD","PIPR","MRNY","AGMB","LU0106261372.USD","LU0912757837.SGD","LU2750360641.GBP","LU0098860793.USD","SGP","LU0096364046.USD","MRNX","LU2133065610.SGD","LU2471134796.USD","MRNA","LU0122379950.USD","AKTS","BK4550","LU2111349929.HKD","LU2028103732.USD","LU0320765992.SGD","LU0889565916.HKD","LU2089283258.USD","LU0251142724.SGD","LU1791807156.HKD","LU2237443465.HKD","BK4552"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129897501","title":"异动解读 | 新股上市遇冷，AgomAb Therapeutics盘中大跌18.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=1129897501","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129897501?lang=zh_cn&edition=fundamental","pubTime":"2026-02-07 01:54","pubTimestamp":1770400445,"startTime":"0","endTime":"0","summary":"AgomAb Therapeutics(AGMB)今日盘中股价大跌18.72%，引起了市场的广泛关注。消息面上，该公司于周五正式登陆美股市场，但新股表现不佳，开盘即大幅下跌。根据相关报道，其IPO价格为16美元，上市后股价持续走低，市场对其首秀反应冷淡。AgomAb Therapeutics是一家总部位于比利时的临床阶段生物制药公司，专注于开发针对免疫与炎症疾病的创新疗法。公司估值约为7.164亿美元，其核心候选药物针对纤维狭窄型克罗恩病等慢性纤维化适应症。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AGMB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/AGMB\",params:#limit:6,delay:false,,,undefined,":[]}}